Amjad Masad said that young people who are not deeply interested in computer science should not study it.

Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...

After initially setting out plans to lay off dozens of workers in Massachusetts, Replimune Group is now increasing those ...

Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...

Our client is a modern data automation and integration platform that enables enterprises to innovate faster by unlocking and optimizing data across multiple services and systems. They provide a ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...

FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...